CN107973779B - 一种n-(2-吡啶/嘧啶基)吲哚衍生物的制备方法 - Google Patents
一种n-(2-吡啶/嘧啶基)吲哚衍生物的制备方法 Download PDFInfo
- Publication number
- CN107973779B CN107973779B CN201810017134.2A CN201810017134A CN107973779B CN 107973779 B CN107973779 B CN 107973779B CN 201810017134 A CN201810017134 A CN 201810017134A CN 107973779 B CN107973779 B CN 107973779B
- Authority
- CN
- China
- Prior art keywords
- pyrimidine
- pyridine
- reaction
- indole
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000002475 indoles Chemical class 0.000 title claims abstract description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title claims abstract description 16
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title abstract description 24
- 238000006243 chemical reaction Methods 0.000 claims abstract description 83
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 44
- -1 2-substituted phenyl aminopyridine Chemical class 0.000 claims abstract description 25
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 22
- 238000004440 column chromatography Methods 0.000 claims abstract description 20
- 150000003230 pyrimidines Chemical class 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 9
- 238000010438 heat treatment Methods 0.000 claims abstract description 8
- 239000003960 organic solvent Substances 0.000 claims abstract description 7
- 229940054051 antipsychotic indole derivative Drugs 0.000 claims abstract description 6
- 238000007363 ring formation reaction Methods 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims abstract description 4
- 238000001816 cooling Methods 0.000 claims abstract description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 53
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 claims description 40
- PBDBXAQKXCXZCJ-UHFFFAOYSA-L palladium(2+);2,2,2-trifluoroacetate Chemical compound [Pd+2].[O-]C(=O)C(F)(F)F.[O-]C(=O)C(F)(F)F PBDBXAQKXCXZCJ-UHFFFAOYSA-L 0.000 claims description 20
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 claims description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000007800 oxidant agent Substances 0.000 abstract description 5
- 239000003054 catalyst Substances 0.000 abstract description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract description 4
- 239000003513 alkali Substances 0.000 abstract description 3
- 230000001590 oxidative effect Effects 0.000 abstract description 3
- 239000000758 substrate Substances 0.000 abstract description 3
- 238000000746 purification Methods 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 230000035484 reaction time Effects 0.000 abstract description 2
- 125000001424 substituent group Chemical group 0.000 abstract description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 52
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 51
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 17
- 238000005160 1H NMR spectroscopy Methods 0.000 description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 17
- 238000012512 characterization method Methods 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- HUDSSSKDWYXKGP-UHFFFAOYSA-N n-phenylpyridin-2-amine Chemical class C=1C=CC=NC=1NC1=CC=CC=C1 HUDSSSKDWYXKGP-UHFFFAOYSA-N 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical group [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- LCPVQAHEFVXVKT-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)pyridin-3-amine Chemical compound NC1=CC=CN=C1OC1=CC=C(F)C=C1F LCPVQAHEFVXVKT-UHFFFAOYSA-N 0.000 description 1
- FSVSDDGJTVTMCH-UHFFFAOYSA-N 2-(2-chlorophenyl)-1-pyridin-2-ylindole Chemical compound ClC1=C(C=CC=C1)C=1N(C2=CC=CC=C2C=1)C1=NC=CC=C1 FSVSDDGJTVTMCH-UHFFFAOYSA-N 0.000 description 1
- IGSMUEPTYJBTQG-UHFFFAOYSA-N 2-(3-chlorophenyl)-1-pyridin-2-ylindole Chemical compound ClC=1C=C(C=CC=1)C=1N(C2=CC=CC=C2C=1)C1=NC=CC=C1 IGSMUEPTYJBTQG-UHFFFAOYSA-N 0.000 description 1
- NWRPBWDTXKZRTI-UHFFFAOYSA-N 2-(4-chlorophenyl)-1-pyridin-2-ylindole Chemical compound Clc1ccc(cc1)-c1cc2ccccc2n1-c1ccccn1 NWRPBWDTXKZRTI-UHFFFAOYSA-N 0.000 description 1
- TVKNAUVTZHRRND-UHFFFAOYSA-N 2-(4-fluorophenyl)-1-pyridin-2-ylindole Chemical compound Fc1ccc(cc1)-c1cc2ccccc2n1-c1ccccn1 TVKNAUVTZHRRND-UHFFFAOYSA-N 0.000 description 1
- GNDVOWLVNORGSZ-UHFFFAOYSA-N 2-phenyl-1-pyridin-2-ylindole Chemical compound C=1C=CC=NC=1N1C2=CC=CC=C2C=C1C1=CC=CC=C1 GNDVOWLVNORGSZ-UHFFFAOYSA-N 0.000 description 1
- LFWFXWJIJCSXKF-UHFFFAOYSA-N 2-phenyl-1-pyridin-2-ylindole-5-carbonitrile Chemical compound C1(=CC=CC=C1)C=1N(C2=CC=C(C=C2C=1)C#N)C1=NC=CC=C1 LFWFXWJIJCSXKF-UHFFFAOYSA-N 0.000 description 1
- XXCZBAPJFSJFLY-UHFFFAOYSA-N 2-phenyl-1-pyrimidin-2-ylindole Chemical compound C1(=CC=CC=C1)C=1N(C2=CC=CC=C2C=1)C1=NC=CC=N1 XXCZBAPJFSJFLY-UHFFFAOYSA-N 0.000 description 1
- RZFIPFCQGIIHKH-UHFFFAOYSA-N 5-chloro-2-phenyl-1-pyridin-2-ylindole Chemical compound ClC=1C=C2C=C(N(C2=CC=1)C1=NC=CC=C1)C1=CC=CC=C1 RZFIPFCQGIIHKH-UHFFFAOYSA-N 0.000 description 1
- CLQHEYJZQRPYGZ-UHFFFAOYSA-N 5-fluoro-2-phenyl-1-pyridin-2-ylindole Chemical compound FC=1C=C2C=C(N(C2=CC=1)C1=NC=CC=C1)C1=CC=CC=C1 CLQHEYJZQRPYGZ-UHFFFAOYSA-N 0.000 description 1
- ARMMBWOOGKEWKR-UHFFFAOYSA-N 5-methyl-2-phenyl-1-pyridin-2-ylindole Chemical compound CC=1C=C2C=C(N(C2=CC=1)C1=NC=CC=C1)C1=CC=CC=C1 ARMMBWOOGKEWKR-UHFFFAOYSA-N 0.000 description 1
- GIDCHRIJMXCSAY-UHFFFAOYSA-N 6-chloro-2-phenyl-1-pyridin-2-ylindole Chemical compound ClC1=CC=C2C=C(N(C2=C1)C1=NC=CC=C1)C1=CC=CC=C1 GIDCHRIJMXCSAY-UHFFFAOYSA-N 0.000 description 1
- WJJOHURMTQILGQ-UHFFFAOYSA-N 6-methyl-2-phenyl-1-pyridin-2-ylindole Chemical compound CC1=CC=C2C=C(N(C2=C1)C1=NC=CC=C1)C1=CC=CC=C1 WJJOHURMTQILGQ-UHFFFAOYSA-N 0.000 description 1
- GHZWOHRPABFKKF-UHFFFAOYSA-N 7-methyl-2-phenyl-1-pyridin-2-ylindole Chemical compound CC=1C=CC=C2C=C(N(C=12)C1=NC=CC=C1)C1=CC=CC=C1 GHZWOHRPABFKKF-UHFFFAOYSA-N 0.000 description 1
- 238000006783 Fischer indole synthesis reaction Methods 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- RBYGDVHOECIAFC-UHFFFAOYSA-L acetonitrile;palladium(2+);dichloride Chemical compound [Cl-].[Cl-].[Pd+2].CC#N.CC#N RBYGDVHOECIAFC-UHFFFAOYSA-L 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WXNOJTUTEXAZLD-UHFFFAOYSA-L benzonitrile;dichloropalladium Chemical compound Cl[Pd]Cl.N#CC1=CC=CC=C1.N#CC1=CC=CC=C1 WXNOJTUTEXAZLD-UHFFFAOYSA-L 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- RULIFSIKXUKYAJ-UHFFFAOYSA-N n-(3-chlorophenyl)pyridin-2-amine Chemical compound ClC1=CC=CC(NC=2N=CC=CC=2)=C1 RULIFSIKXUKYAJ-UHFFFAOYSA-N 0.000 description 1
- CEEVFEYBASJQHU-UHFFFAOYSA-N n-(3-fluorophenyl)pyridin-2-amine Chemical compound FC1=CC=CC(NC=2N=CC=CC=2)=C1 CEEVFEYBASJQHU-UHFFFAOYSA-N 0.000 description 1
- PRZYJLBEQGBXQQ-UHFFFAOYSA-N n-(4-chlorophenyl)pyridin-2-amine Chemical compound C1=CC(Cl)=CC=C1NC1=CC=CC=N1 PRZYJLBEQGBXQQ-UHFFFAOYSA-N 0.000 description 1
- DSVOTYHSTIRRCO-UHFFFAOYSA-N n-(4-fluorophenyl)pyridin-2-amine Chemical compound C1=CC(F)=CC=C1NC1=CC=CC=N1 DSVOTYHSTIRRCO-UHFFFAOYSA-N 0.000 description 1
- CKCDXUMOIWFAQJ-UHFFFAOYSA-N n-(4-methylphenyl)pyridin-2-amine Chemical compound C1=CC(C)=CC=C1NC1=CC=CC=N1 CKCDXUMOIWFAQJ-UHFFFAOYSA-N 0.000 description 1
- XGXNTJHZPBRBHJ-UHFFFAOYSA-N n-phenylpyrimidin-2-amine Chemical compound N=1C=CC=NC=1NC1=CC=CC=C1 XGXNTJHZPBRBHJ-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical group [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 description 1
- 229940071536 silver acetate Drugs 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- KKKDGYXNGYJJRX-UHFFFAOYSA-M silver nitrite Chemical compound [Ag+].[O-]N=O KKKDGYXNGYJJRX-UHFFFAOYSA-M 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Substances [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
本发明公开了一种N‑(2‑吡啶/嘧啶基)吲哚衍生物的制备方法,包括如下步骤:将2‑取代苯基氨基吡啶/嘧啶衍生物、烯基叠氮化合物、催化剂、氧化剂、碱、有机溶剂混匀后在氮气或空气下加热至60~80℃进行环化反应18~24h,反应结束冷却至室温,经浓缩及柱层析纯化,得到所述N‑(2‑吡啶/嘧啶基)吲哚衍生物。本发明可合成其他方法不能合成的具有多种取代基的N‑(2‑吡啶/嘧啶基)吲哚衍生物,且所用原料易得,收率高,反应条件温和,反应时间短,底物范围广,反应专一性强,后处理简便且绿色。
Description
技术领域
本发明属于有机合成技术领域,具体涉及一种N-(2-吡啶/嘧啶基)吲哚衍生物的制备方法。
背景技术
N-(2-吡啶/嘧啶基)吲哚衍生物是一类用途广泛的有机合成中间体,在天然产物、医药生产、有机合成中均具有重要的应用价值。因此,研究多取代吲哚的新制备方法具有重要的应用价值,受到相关领域科研工作者的关注。
传统合成N-(2-吡啶/嘧啶基)吲哚衍生物方法包括Fischer吲哚合成;Larock吲哚合成;过渡金属催化的2-多取代苯基氨基吡啶衍生物与1,2-二取代炔烃的环化反应等。上述方法通常存在如下问题:1)反应区域选择性差,副产物多;2)使用价格昂贵的过渡金属;3)醋酸铜作氧化剂,环境不友好;4)反应温度高,对设备要求苛刻;5)底物适用范围较窄。
发明内容
本发明的目的在于克服现有技术缺陷,提供一种N-(2-吡啶/嘧啶基)吲哚衍生物的制备方法。
本发明的技术方案如下:
包括如下步骤:将2-取代苯基氨基吡啶/嘧啶衍生物、烯基叠氮化合物、催化剂、氧化剂、碱、有机溶剂混匀后在氮气或空气下加热至60~80℃进行环化反应18~24h,反应结束冷却至室温,经浓缩及柱层析纯化,得到所述N-(2-吡啶/嘧啶基)吲哚衍生物,2- 取代苯基氨基吡啶/嘧啶衍生物与烯基叠氮化合物的摩尔比为1∶1.5~2,每摩尔2-取代苯基氨基吡啶/嘧啶衍生物对应0.5~1L有机溶剂
其中,R1、R2、R3和R4均选自氢原子、卤素原子、烷基、氰基、硝基、羰基、三氟甲基和烷氧基中的一种,R5为苯基或者取代芳基。
在本发明的一个优选实施方案中,所述催化剂为醋酸钯、三氟乙酸钯、双(乙腈)氯化钯、二(苯腈)二氯化钯或氯化钯。
在本发明的一个优选实施方案中,所述氧化剂为过硫酸钠、过硫酸钾、硝酸银、亚硝酸银、醋酸银和六氟锑酸银中的至少一种。
在本发明的一个优选实施方案中,所述溶剂为二氯甲烷、四氢呋喃、甲醇、1,2-二氯乙烷、甲苯、乙醇、乙腈、乙酸乙酯、氯苯、N-甲基吡咯烷酮及1,4-二氧六环中的至少一种。
在本发明的一个优选实施方案中,所述碱为碳酸钠、醋酸钠、三乙烯二胺或碳酸氢钠。
在本发明的一个优选实施方案中,所述加热的方式为油浴加热。
在本发明的一个优选实施方案中,将2-取代苯基氨基吡啶/嘧啶衍生物、烯基叠氮化合物、催化剂、氧化剂、碱、有机溶剂混匀后在氮气或空气下加热至70~75℃进行环化反应20~24h。
本发明的有益效果是:本发明可合成其他方法不能合成的具有多种取代基的N-(2- 吡啶/嘧啶基)吲哚衍生物,且所用原料易得,收率高,反应条件温和,反应时间短,底物范围广,反应专一性强,后处理简便且绿色。
具体实施方式
以下通过具体实施方式对本发明的技术方案进行进一步的说明和描述。
实施例1
2-苯基-1-(2-吡啶基)吲哚的制备:
在氮气条件下,将N-苯基吡啶-2-胺0.2mmol,(1-烯基叠氮)苯0.3mmol,三氟乙酸钯0.01mmol,过硫酸钾0.4mmol,三乙烯二胺0.08mmol添加至含1mL-1.5mL甲苯的反应管中,置于75℃的油浴中,反应24h,将反应移出热源,冷却至室温。反应液经硅藻土过滤后浓缩,柱层析纯化得到48mg目标产物,收率为89%。该化合物的核磁表征如下:1H NMR(400MHz,CDCl3)δ8.62(dd,J=4.9,1.2Hz,1H),7.68(d,J =4.4Hz,1H),7.66(dd,J=5.0,1.6Hz,1H),7.60(ddd,J=7.8,2.0Hz, 1H),7.31-7.19(m,8H),6.88(d,J=8.0Hz,1H),6.80(s,1H);13C NMR(101MHz,CDCl3)δ152.1,149.2,139.9,138.5,137.7,132.7,132.7, 128.7,128.3,127.4,123.0,122.0,121.6,121.3,120.6,111.5,105.6.
实施例2
2-苯基-1-(2-嘧啶基)吲哚的制备:
在氮气条件下,将N-苯基嘧啶-2-胺0.2mmol,(1-烯基叠氮)苯0.3mmol,三氟乙酸钯 0.01mmol,过硫酸钾0.4mmol,三乙烯二胺0.08mmol添加至含1mL-1.5mL甲苯的反应管中,置于75℃的油浴中,反应24h,将反应移出热源,冷却至室温。反应液经硅藻土过滤后浓缩,柱层析纯化得到36mg目标产物,收率为66%。该化合物的核磁表征如下:1H NMR(400MHz,CDCl3)δ8.67(d,J=4.8Hz,1H),8.13(d,J=8.1Hz, 1H),7.65(d,J=7.7Hz,1H),7.30-7.22(m,3H),7.10(d,J=4.8Hz, 1H),6.81(s,1H);13C NMR(101MHz,CDCl3)δ158.2,140.5,138.1,133.9, 129.3,129.3,128.15,128.1,127.1,123.5,122.1,120.7,117.6,112.8,108.2.
实施例3
5-甲基-2-苯基-1-(2-吡啶基)吲哚的制备:
在氮气条件下,将N-(对甲苯基)吡啶-2-胺0.2mmol,(1-烯基叠氮)苯0.3mmol,三氟乙酸钯0.01mmol,过硫酸钾0.4mmol,三乙烯二胺0.08mmol添加至含1mL-1.5mL甲苯的反应管中,置于75℃的油浴中,反应24h,将反应移出热源,冷却至室温。反应液经硅藻土过滤后浓缩,柱层析纯化得到47mg目标产物,收率为83%。该化合物的核磁表征如下:1H NMR(400MHz,CDCl3)δ8.58(d,J=4.9Hz,1H),7.57(d, J=8.4Hz,1H),7.52(dd,J=6.9Hz,1H),7.42(s,1H),7.24-7.17(m, 4H),7.12(dd,J=7.4,4.9Hz,1H),7.03(d,J=8.4Hz,1H),6.82(d, J=8.0Hz,1H),6.71(s,1H),2.44(s,3H);13C NMR(101MHz,CDCl3) δ152.2,149.0,139.9,137.6,136.9,132.8,130.5,128.9,128.6,128.2,127.2, 124.5,121.7,121.3,120.2,111.2,105.3,21.3.
实施例4
2-苯基-5-氟-1-(2-吡啶基)吲哚的制备:
在氮气条件下,将N-(4-氟苯基)吡啶-2-胺0.2mmol,(1-烯基叠氮)苯0.3mmol,三氟乙酸钯0.01mmol,过硫酸钾0.4mmol,三乙烯二胺0.08mmol添加至含1mL-1.5mL甲苯的反应管中,置于75℃的油浴中,反应24h,将反应移出热源,冷却至室温。反应液经硅藻土过滤后浓缩,柱层析纯化得到44mg目标产物,收率为76%。该化合物的核磁表征如下:1H NMR(400MHz,CDCl3)δ8.62(d,J=4.7Hz,1H),7.66-7.55(m, 2H),7.29-7.18(m,7H),6.95(ddd,J=9.1,1.1Hz,1H),6.82(d, J=8.0Hz,1H),6.74(s,1H);13C NMR(101MHz,CDCl3)δ159.9(d,JF-C=236.6Hz),151.9,149.2,141.5,137.8,135.0,132.4,129.2(d,JF-C=10.1 Hz),128.7,128.4,127.7,121.9,121.8,112.5(d,JF-C=9.3Hz),111.2(d, JF-C=25.8Hz),105.5(d,JF-C=23.6Hz),105.3(d,JF-C=4.5Hz).
实施例5
2-苯基-5-氯-1-(2-吡啶基)吲哚的制备:
在氮气条件下,将N-(4-氯苯基)吡啶-2-胺0.2mmol,(1-烯基叠氮)苯0.3mmol,三氟乙酸钯0.01mmol,过硫酸钾0.4mmol,三乙烯二胺0.08mmol添加至含1mL-1.5mL甲苯的反应管中,置于75℃的油浴中,反应24h,将反应移出热源,冷却至室温。反应液经硅藻土过滤后浓缩,柱层析纯化得到44mg目标产物,收率为72%。该化合物的核磁表征如下:1H NMR(400MHz,d6-DMSO)δ8.67(d,J=4.7Hz,1H),7.87(ddd, J=7.8,1.9Hz,1H),7.74-7.69(m,1H),7.47(d,J=8.8Hz,1H),7.43 (dd,J=6.5,4.9Hz,1H),7.35-7.25(m,3H),7.23(dd,J=7.5,2.1 Hz,2H),7.19(dd,J=8.8,2.1Hz,1H),7.12(d,J=8.0Hz,1H),6.88 (s,1H):13CNMR(101MHz,d6-DMSO)δ150.7,149.4,141.3,138.9,136.6, 131.6,129.3,128.5,128.3,127.9,125.6,122.9,122.7,122.0,119.7,1128, 104.3.
实施例6
2-苯基-5-氰基-1-(2-吡啶基)吲哚的制备:
在氮气条件下,将N-(4-氰基苯)吡啶-2-胺0.2mmol,(1-烯基叠氮)苯0.3mmol,三氟乙酸钯0.01mmol,过硫酸钾0.4mmol,三乙烯二胺0.08mmol添加至含1mL-1.5mL甲苯的反应管中,置于75℃的油浴中,反应24h,将反应移出热源,冷却至室温。反应液经硅藻土过滤后浓缩,柱层析纯化得到30mg目标产物,收率为50%。该化合物的核磁表征如下:1H NMR(400MHz,CDCl3)δ8.67(ddd,J=4.9,1.9,0.7Hz,1H), 8.00(d,J=1.0Hz,1H),7.70(d,J=8.7Hz,1H),7.68-7.64(m,1H), 7.44(dd,J=8.6,1.6Hz,1H),7.32-7.25(m,6H),6.88(d,J=8.0Hz, 1H),6.84(s,1H);13C NMR(101MHz,CDCl3)δ151.0,149.4,142.3,139.8, 138.1,131.5,128.9,128.5,128.4,128.2,125.8,125.8,122.5,122.1,120.5, 112.5,105.2,104.4.
实施例7
6-甲基-2-苯基-1-(2-吡啶基)吲哚的制备:
在氮气条件下,将N-(3-甲基苯)吡啶-2-胺0.2mmol,(1-烯基叠氮)苯0.3mmol,三氟乙酸钯0.01mmol,过硫酸钾0.4mmol,三乙烯二胺0.08mmol添加至含1mL-1.5mL甲苯的反应管中,置于75℃的油浴中,反应24h,将反应移出热源,冷却至室温。反应液经硅藻土过滤后浓缩,柱层析纯化得到47mg目标产物,收率为83%。该化合物的核磁表征如下:1H NMR(400MHz,CDCl3)δ8.70(d,J=5.5Hz,1H),7.68-7.62 (m,1H),7.60(d,J=8.0Hz,1H),7.54(s,1H),7.32-7.29(m,4H), 7.25(ddd,J=7.4,4.9,1.0Hz,1H),7.09(d,J=8.0Hz,1H),6.92(d, J=8.0Hz,1H),6.81(s,1H),2.51(s,3H);13C NMR(101MHz,CDCl3) δ152.3,149.2,139.5,139.0,137.8,133.0,132.9,128.7,128.3,127.3,126.6, 123.1,122.1,121.5,120.3,111.5,105.6,22.0.
实施例8
2-苯基-6-氯-1-(2-吡啶基)吲哚的制备:
在氮气条件下,将N-(3-氯苯基)吡啶-2-胺0.2mmol,(1-烯基叠氮)苯0.3mmol,三氟乙酸钯0.01mmol,过硫酸钾0.4mmol,三乙烯二胺0.08mmol添加至含1mL-1.5mL甲苯的反应管中,置于75℃的油浴中,反应24h,将反应移出热源,冷却至室温。反应液经硅藻土过滤后浓缩,柱层析纯化得到52mg目标产物,收率为85%。该化合物的核磁表征如下:1H NMR(400MHz,d6-DMSO)δ8.63(ddd,J=4.8,1.8,0.7Hz, 1H),7.86(td,J=7.8,1.9Hz,1H),7.66-7.64(m,1H),7.63(d,J =8.4Hz,1H),7.43(ddd,J=7.5,4.9,0.9Hz,1H),7.35-7.26(m,4H), 7.26-7.19(m,2H),7.09(d,J=8.0Hz,1H),6.91(d,J=0.6Hz,1H);13C NMR(101MHz,d6-DMSO)δ150.8,149.7,140.9,139.1,139.0,131.8, 128.7,128.5,128.1,127.4,124.3,123.1,122.5,122.2,115.6,114.1,105.1.
实施例9
2-苯基-6-溴-1-(2-吡啶基)吲哚的制备:
在氮气条件下,将N-(3-溴苯基)吡啶-2-胺0.2mmol,(1-烯基叠氮)苯0.3mmol,三氟乙酸钯0.01mmol,过硫酸钾0.4mmol,三乙烯二胺0.08mmol添加至含1mL-1.5mL甲苯的反应管中,置于75℃的油浴中,反应24h,将反应移出热源,冷却至室温。反应液经硅藻土过滤后浓缩,柱层析纯化得到49mg目标产物,收率为70%。该化合物的核磁表征如下:1H NMR(400MHz,d6-DMSO)δ8.63(ddd,J=4.9,1.8,0.7Hz, 1H),7.85(td,J=7.7,1.9Hz,1H),7.67(d,J=8.4Hz,1H),7.51(d, J=1.9Hz,1H),7.42(ddd,J=7.5,4.9,0.9Hz,1H),7.33-7.27(m,3H), 7.25-7.17(m,3H),7.09(d,J=8.0Hz,1H),6.91(s,1H);13C NMR(101 MHz,d6-DMSO)δ151.1,149.9,141.3,139.4,138.9,132.1,129.0,128.7, 128.3,127.9,127.4,123.4,122.4,122.4,122.0,111.46,105.3.
实施例10
2-苯基-4-氟-1-(2-吡啶基)吲哚的制备:
在氮气条件下,将N-(3-氟苯基)吡啶-2-胺0.2mmol,(1-烯基叠氮)苯0.3mmol,三氟乙酸钯0.01mmol,过硫酸钾0.4mmol,三乙烯二胺0.08mmol添加至含1mL-1.5mL甲苯的反应管中,置于75℃的油浴中,反应24h,将反应移出热源,冷却至室温。反应液经硅藻土过滤后浓缩,柱层析纯化得到40mg目标产物,收率为70%。该化合物的核磁表征如下:1H NMR(400MHz,CDCl3)δ8.63(m,J=4.9,1.9,0.7Hz,1H), 7.61-7.51(m,2H),7.43(dd,J=10.2,2.3Hz,1H),7.25-7.22(m,5H), 7.20(m,J=7.4,4.9,0.9Hz,1H),6.95(m,J=9.4,8.7,2.4Hz,1H), 6.82(d,J=8.1Hz,1H),6.75(s,1H);13CNMR(101MHz,CDCl3)δ161.6 (d,JF-C=238Hz),151.8,149.2,140.4(d,JF-C=3.9Hz),138.6(d,JF-C= 12.5Hz),137.8,132.4,128.6,128.4,127.5,125.1,121.7,121.7,121.3(d, JF-C=9.9Hz),110.0(d,JF-C=24.5Hz),105.4,98.6(d,JF-C=27.6Hz).
实施例11
7-甲基-2-苯基-1-(2-吡啶基)吲哚的制备:
在氮气条件下,将N-(2-甲基苯)吡啶-2-胺0.2mmol,(1-烯基叠氮)苯0.3mmol,三氟乙酸钯0.01mmol,过硫酸钾0.4mmol,三乙烯二胺0.08mmol添加至含1mL-1.5mL甲苯的反应管中,置于75℃的油浴中,反应24h,将反应移出热源,冷却至室温。反应液经硅藻土过滤后浓缩,柱层析纯化得到36mg目标产物,收率为64%。该化合物的核磁表征如下:1H NMR(400MHz,d6-DMSO)δ8.63(ddd,J=4.9,1.9,0.7Hz, 1H),7.85(td,J=7.7,2.0Hz,1H),7.55-7.52(m,1H),7.52-7.47(m, 1H),7.36(d,J=7.8Hz,1H),7.26-7.19(m,4H),7.04(t,J=7.5Hz, 1H),6.91(d,J=7.1Hz,1H),6.80(s,1H),1.78(s,3H);13C NMR (101MHz,d6-DMSO)δ152.7,148.7,141.3,138.2,137.3,132.2,128.7,128.3, 128.2,127.5,125.4,125.0,124.3,121.2,120.6,118.6,103.5,18.8.
实施例12
2-对甲苯-1-(2-吡啶基)吲哚的制备:
在氮气条件下,将2-苯基氨基吡啶0.2mmol,4-甲基-1-(1-烯基叠氮)苯0.3mmol,三氟乙酸钯0.01mmol,过硫酸钾0.4mmol,三乙烯二胺0.08mmol添加至含1mL-1.5mL甲苯的反应管中,置于75℃的油浴中,反应24h,将反应移出热源,冷却至室温。反应液经硅藻土过滤后浓缩,柱层析纯化得到51mg目标产物,收率为90%。该化合物的核磁表征如下:1H NMR(400MHz,CDCl3)δ8.64-8.57(m,1H),7.72-7.62(m, 2H),7.57(td,J=7.8,1.9Hz,1H),7.23-7.17(m,3H),7.14(s,1H), 7.07(s,1H),7.05(s,1H),6.87(d,J=8.0Hz,1H),6.76(s,1H), 2.31(s,3H);13CNMR(101MHz,CDCl3)δ152.1,149.1,140.0,138.4,137.7, 137.2,129.7,129.0,128.7,128.6,122.8,122.0,121.5,121.2,120.4,111.4, 105.1,21.1.
实施例13
2-(4-氟-苯基)-1-(2-吡啶基)吲哚的制备:
在氮气条件下,将2-苯基氨基吡啶0.2mmol,4-氟-1-(1-烯基叠氮)苯0.3mmol,三氟乙酸钯0.01mmol,过硫酸钾0.4mmol,三乙烯二胺0.08mmol添加至含1mL-1.5mL甲苯的反应管中,置于75℃的油浴中,反应24h,将反应移出热源,冷却至室温。反应液经硅藻土过滤后浓缩,柱层析纯化得到42mg目标产物,收率为74%。该化合物的核磁表征如下:1H NMR(400MHz,CDCl3)δ8.60(ddd,J=4.9,1.9,0.7Hz,1H), 7.67-7.57(m,3H),7.24-7.16(m,5H),6.99-6.90(m,2H),6.88(d, J=8.0Hz,1H),6.75(s,1H);13C NMR(101MHz,CDCl3)δ163.4(d,J =247.5Hz),151.8,149.2,138.9,138.4,137.8,130.4(d,J=7.9Hz),128.8(d,J=3.3Hz),128.6,123.0,121.9(d,J=17.7Hz),121.4,120.5,115.4, 115.2,111.4,105.4.
实施例14
2-(4-氯-苯基)-1-(2-吡啶基)吲哚的制备:
在氮气条件下,将2-苯基氨基吡啶0.2mmol,4-氯-1-(1-烯基叠氮)苯0.3mmol,三氟乙酸钯0.01mmol,过硫酸钾0.4mmol,三乙烯二胺0.08mmol添加至含1mL-1.5mL甲苯的反应管中,置于75℃的油浴中,反应24h,将反应移出热源,冷却至室温。反应液经硅藻土过滤后浓缩,柱层析纯化得到51mg目标产物,收率为84%。该化合物的核磁表征如下:1H NMR(400MHz,CDCl3)δ8.63-8.55(m,1H),7.86-7.34(m, 4H),7.24-7.17(m,6H),6.89(d,J=8.0Hz,1H),6.77(s,1H);13C NMR(101MHz,CDCl3)δ151.7,149.3,138.6,138.5,137.9,133.3,131.1,131.1,129.7,128.5,123.2,121.8,121.8,121.4,120.6,111.4,105.8.
实施例15
2-(3-氯-苯基)-1-(2-吡啶基)吲哚的制备:
在氮气条件下,将2-苯基氨基吡啶0.2mmol,3-氯-1-(1-烯基叠氮)苯0.3mmol,三氟乙酸钯0.01mmol,过硫酸钾0.4mmol,三乙烯二胺0.08mmol添加至含1mL-1.5mL甲苯的反应管中,置于75℃的油浴中,反应24h,将反应移出热源,冷却至室温。反应液经硅藻土过滤后浓缩,柱层析纯化得到49mg目标产物,收率为81%。该化合物的核磁表征如下:1H NMR(400MHz,CDCl3)δ8.62(dd,J=4.9,1.4Hz,1H),7.69- 7.61(m,3H),7.33(t,J=1.7Hz,1H),7.24-7.17(m,4H),7.15(t, J=7.8Hz,1H),7.05(d,J=7.6Hz,1H),6.95(d,J=8.0Hz,1H),6.82 (s,1H);13C NMR(101MHz,CDCl3)δ151.7,149.3,138.6,138.4,137.9, 134.5,134.2,134.2,129.4,128.5,127.4,126.8,123.4,121.9,121.9,121.5, 120.8,111.4,106.3.
实施例16
2-邻甲苯-1-(2-吡啶基)吲哚的制备:
在氮气条件下,将2-苯基氨基吡啶0.2mmol,2-甲基-1-(1-烯基叠氮)苯0.3mmol,三氟乙酸钯0.01mmol,过硫酸钾0.4mmol,三乙烯二胺0.08mmol添加至含1mL-1.5mL甲苯的反应管中,置于75℃的油浴中,反应24h,将反应移出热源,冷却至室温。反应液经硅藻土过滤后浓缩,柱层析纯化得到28mg目标产物,收率为50%。该化合物的核磁表征如下:1H NMR(400MHz,CDCl3)δ8.57(ddd,J=4.9,1.9,0.7Hz,1H),7.90-7.79(m,1H),7.67(m,J=10.4,4.8Hz,1H),7.51-7.45(m,1H), 7.32-7.10(m,7H),6.70(d,J=8.1Hz,1H),6.66(d,J=0.6Hz,1H), 2.06(s,3H);13C NMR(101MHz,CDCl3)δ151.9,148.9,139.0,137.5,137.4,137.2,132.7,131.1,130.2,128.6,128.3,125.6,122.8,121.2,121.0,120.5, 120.4,112.0,106.2,20.1.
实施例17
2-(2-氯-苯基)-1-(2-吡啶基)吲哚的制备:
在氮气条件下,将2-苯基氨基吡啶0.2mmol,2-氯-1-(1-烯基叠氮)苯0.3mmol,三氟乙酸钯0.01mmol,过硫酸钾0.4mmol,三乙烯二胺0.08mmol添加至含1mL-1.5mL甲苯的反应管中,置于75℃的油浴中,反应24h,将反应移出热源,冷却至室温。反应液经硅藻土过滤后浓缩,柱层析纯化得到41mg目标产物,收率为68%。该化合物的核磁表征如下:1H NMR(400MHz,CDCl3)δ8.52(dd,J=4.9,1.2Hz,1H),7.81 (d,J=8.3Hz,1H),7.69(d,J=7.4Hz,1H),7.56(m,J=7.8,1.9Hz, 1H),7.35(m,J=10.9,7.5,4.1Hz,2H),7.24(m,J=8.9,6.7,6.1,1.4 Hz,4H),7.13(dd,J=6.6,4.9Hz,1H),6.88(d,J=8.1Hz,1H),6.79 (s,1H);13CNMR(101MHz,CDCl3)δ151.7,148.9,137.6,137.2,136.4, 133.9,132.6,132.3,129.7,129.3,128.4,126.5,123.3,121.3,121.2,120.7, 120.3,111.8,107.4.
以上所述,仅为本发明的较佳实施例而已,故不能依此限定本发明实施的范围,即依本发明专利范围及说明书内容所作的等效变化与修饰,皆应仍属本发明涵盖的范围内。
Claims (4)
包括如下步骤:将2-取代苯基氨基吡啶/嘧啶衍生物、烯基叠氮化合物、三氟乙酸钯、过硫酸钾、三乙烯二胺、有机溶剂混匀后在氮气或空气下加热至60~80℃进行环化反应18~24h,反应结束冷却至室温,经浓缩及柱层析纯化,得到所述N-(2-吡啶/嘧啶基)吲哚衍生物,2-取代苯基氨基吡啶/嘧啶衍生物与烯基叠氮化合物的摩尔比为1:1.5~2,每摩尔2-取代苯基氨基吡啶/嘧啶衍生物对应0.5~1L有机溶剂
其中,R1、R2、R3和R4均选自氢原子、卤素原子、烷基、氰基、硝基、三氟甲基和烷氧基中的一种,R5为苯基或者取代芳基。
2.如权利要求1所述的制备方法,其特征在于:所述溶剂为二氯甲烷、四氢呋喃、甲醇、1,2-二氯乙烷、甲苯、乙醇、乙腈、乙酸乙酯、氯苯、N-甲基吡咯烷酮及1,4-二氧六环中的至少一种。
3.如权利要求1所述的制备方法,其特征在于:所述加热的方式为油浴加热。
4.如权利要求1所述的制备方法,其特征在于:将2-取代苯基氨基吡啶/嘧啶衍生物、烯基叠氮化合物、三氟乙酸钯、过硫酸钾、三乙烯二胺、有机溶剂混匀后在氮气或空气下加热至70~75℃进行环化反应20~24h。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810017134.2A CN107973779B (zh) | 2018-01-08 | 2018-01-08 | 一种n-(2-吡啶/嘧啶基)吲哚衍生物的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810017134.2A CN107973779B (zh) | 2018-01-08 | 2018-01-08 | 一种n-(2-吡啶/嘧啶基)吲哚衍生物的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107973779A CN107973779A (zh) | 2018-05-01 |
CN107973779B true CN107973779B (zh) | 2020-05-05 |
Family
ID=62005947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810017134.2A Expired - Fee Related CN107973779B (zh) | 2018-01-08 | 2018-01-08 | 一种n-(2-吡啶/嘧啶基)吲哚衍生物的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107973779B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110511208B (zh) * | 2019-08-02 | 2020-08-25 | 浙江工业大学 | N-2-吡啶基-2,3-二叠氮吲哚啉类化合物及其制备与应用 |
CN111807942B (zh) * | 2020-08-05 | 2022-11-18 | 厦门华厦学院 | 一种多取代茚酮衍生物的制备方法 |
CN112010722B (zh) * | 2020-09-14 | 2023-01-06 | 南通大学 | 一种E型β-硫氰烯酰胺衍生物的合成方法 |
CN113214252B (zh) * | 2021-05-28 | 2022-02-11 | 常州大学 | 6-苯基-7-(吡啶-2-基)-7H-吲哚并[2,3-c]喹啉化合物的合成方法 |
CN115260016B (zh) * | 2022-08-30 | 2023-11-24 | 苏州爱玛特生物科技有限公司 | 一种苯基环烷基衍生物的合成方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103012241A (zh) * | 2013-01-23 | 2013-04-03 | 中国科学院上海有机化学研究所 | 多取代吲哚、合成方法及其应用于吲哚美辛的合成 |
CN107098847A (zh) * | 2017-04-26 | 2017-08-29 | 华侨大学 | 一种1‑氨基吲哚衍生物的制备方法 |
-
2018
- 2018-01-08 CN CN201810017134.2A patent/CN107973779B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103012241A (zh) * | 2013-01-23 | 2013-04-03 | 中国科学院上海有机化学研究所 | 多取代吲哚、合成方法及其应用于吲哚美辛的合成 |
CN107098847A (zh) * | 2017-04-26 | 2017-08-29 | 华侨大学 | 一种1‑氨基吲哚衍生物的制备方法 |
Non-Patent Citations (2)
Title |
---|
Miguel Peña-López et al..Ruthenium-Catalyzed Synthesis of Indoles from Anilines and Epoxides.《Chem. Eur. J.》.2014,第20卷第1818-1824页. * |
基于多米诺反应合成吲哚衍生物;冯亚栋等;《有机化学》;20141231;第34卷;第1499-1508页 * |
Also Published As
Publication number | Publication date |
---|---|
CN107973779A (zh) | 2018-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107973779B (zh) | 一种n-(2-吡啶/嘧啶基)吲哚衍生物的制备方法 | |
JP5030206B2 (ja) | 1,2−ジヒドロピリジン−2−オン化合物の製造方法 | |
CN111315742B (zh) | 制备氨基嘧啶衍生物的方法 | |
CN110204486B (zh) | 一种喹啉衍生物的合成方法 | |
CN111675662A (zh) | 一种2-三氟甲基取代的喹唑啉酮化合物的制备方法 | |
KR101320752B1 (ko) | 벤조이미다졸 유도체의 신규한 제조방법 | |
CN109535086B (zh) | 一种喹喔啉-2(1h)-酮c-3位羧酸酯化合物的合成方法 | |
CN109651271B (zh) | 一种3-叔丁基-n-甲基喹喔啉-2(1h)-酮化合物的合成方法 | |
CN113845509B (zh) | 吲哚基取代螺[环丁烷-1,1′-茚]类化合物的合成方法 | |
CN112047879B (zh) | 一种铜催化选择性合成卤代芳胺的方法 | |
JP2020528437A (ja) | アミノピリミジン誘導体の合成に有用な新規中間体、それを調製するためのプロセス、及びそれを使用してアミノピリミジン誘導体を調製するためのプロセス | |
US6340772B2 (en) | Process for preparing (hetero) aromatic substituted benzene derivatives | |
CN112851652B (zh) | 一种2-(取代氧杂蒽基)苯并呋喃类化合物的催化氧化合成方法 | |
CN110483391B (zh) | 一种烟酰亚胺酰胺衍生物的五组分合成方法 | |
CN109912640B (zh) | 一种2-吡咯烷酮类化合物的制备方法 | |
CN108484602B (zh) | 一种多取代氮杂三环嗪衍生物的制备方法 | |
CN106957254B (zh) | 一种3-烷氧基烷基吲哚衍生物及其制备方法和应用 | |
Liu et al. | Rhodium-catalyzed C–H carboxymethylation of anilines with vinylene carbonate | |
CN111592549B (zh) | 一种喹唑啉酮衍生物的制备方法 | |
CN114349684B (zh) | 一种苯并[c,d]吲哚亚胺衍生物的合成方法 | |
KR101580821B1 (ko) | 디메틸설폭사이드 용매하에서 호기성 산화법을 이용한 퀴나졸리논 유도체의 제조방법 | |
CN113150008B (zh) | Dbu催化下多取代2-氧杂双环[2,2,2]辛烷-3-亚胺衍生物的合成方法 | |
CN109020972B (zh) | 一种三唑并[1,5-a]喹啉衍生物的制备方法 | |
JP2011519919A (ja) | 不斉水素化のための触媒的プロセス | |
JP7175085B2 (ja) | トリアジン化合物の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200505 |
|
CF01 | Termination of patent right due to non-payment of annual fee |